Roka Bioscience (NASDAQ: ROKA) is one of 188 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Roka Bioscience to related companies based on the strength of its earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.
This table compares Roka Bioscience and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Roka Bioscience Competitors||-3,314.45%||-537.18%||-41.41%|
Roka Bioscience has a beta of 2.29, indicating that its share price is 129% more volatile than the S&P 500. Comparatively, Roka Bioscience’s competitors have a beta of 1.53, indicating that their average share price is 53% more volatile than the S&P 500.
This is a summary of recent ratings and target prices for Roka Bioscience and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Roka Bioscience Competitors||511||2400||6602||122||2.66|
Roka Bioscience presently has a consensus price target of $10.00, suggesting a potential upside of 861.54%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.99%. Given Roka Bioscience’s stronger consensus rating and higher probable upside, research analysts clearly believe Roka Bioscience is more favorable than its competitors.
Valuation & Earnings
This table compares Roka Bioscience and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Roka Bioscience||$7.24 million||-$30.78 million||-0.12|
|Roka Bioscience Competitors||$215.30 million||-$39.34 million||-73.35|
Roka Bioscience’s competitors have higher revenue, but lower earnings than Roka Bioscience. Roka Bioscience is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Institutional & Insider Ownership
48.6% of Roka Bioscience shares are held by institutional investors. Comparatively, 49.9% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 29.2% of Roka Bioscience shares are held by insiders. Comparatively, 14.8% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Roka Bioscience beats its competitors on 8 of the 12 factors compared.
Roka Bioscience Company Profile
Roka Bioscience, Inc. is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications. The detection of foodborne pathogens is accomplished using culture-based assays, immunochemical-based assays and molecular-based assays. The Company sells its Atlas Detection Assays and related consumable supplies for use with its Atlas instruments. The Company’s Atlas instrument is an automated molecular diagnostic testing and a sample-in-result-out instrument that eliminates the need for batch processing and automates all aspects of molecular diagnostic testing on a single, integrated platform.
Receive News & Ratings for Roka Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roka Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.